Multiple Myeloma

Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.

Most patients treated with talquetamab at a single center would not have qualified for MonumenTAL-1, yet responses were similar regardless of trial eligibility.

The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.

Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.

Denosumab-adet (Degevma) is FDA-approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and hypercalcemia of malignancy.

The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.

The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.

After nearly 7 years of follow-up, daratumumab added to VRd continued to improve PFS, PFS2, and sustained MRD negativity in transplant-eligible myeloma.

Monthly etentamig significantly improved response and PFS over standard available therapies in the phase 3 CERVINO trial, with low rates of high-grade CRS.

Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across 2 cevostamab dose levels, supporting selection of a recommended phase 3 regimen.

A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.

Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.

Ja Min Byun, MD, PhD, discusses updated phase 1 findings with mezigdomide plus elranatamab in relapsed/refractory multiple myeloma.

The positive CHMP opinion for teclistamab in second- and later-line relapsed/refractory multiple myeloma is supported by MajesTEC-9 data.

CHMP offerred a positive opinion supporting extension of melflufen to third-line, lenalidomide-refractory multiple myeloma.

The latest updates to the NCCN Guidelines for multiple myeloma expand minimal residual disease testing guidance.

The FDA approved sevabertinib in first-line HER2-mutant lung cancer, durvalumab plus tarlatamab boosted survival in ES-SCLC, and more.

Prophylactic tocilizumab before step-up dosing lowered CRS rates approximately 5-fold with teclistamab and talquetamab in relapsed/refractory myeloma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Arlocabtagene autoleucel met the primary end point of overall response rate in the registrational phase 2 QUINTESSENTIAL trial.

Patients with triple-class–exposed relapsed/refractory multiple myeloma reported improvements in pain, fatigue, and functioning during up to 2 years of linvoseltamab.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.

Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.